)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Compugen
Compugen (CGEN) investor relations material
Compugen KOL event summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.KOL event summary5 Oct, 2026
Introduction and agenda
Event covered COM701 in ovarian cancer and the continued evolution of Unigen; no new targets were disclosed.
Interim MAIA-ovarian PFS analysis expected by Q1 2027.
KOL background and credentials
Dr. Oladapo Yeku, MAIA-ovarian lead investigator at Harvard and Massachusetts General Hospital, discussed ovarian cancer treatment and COM701’s maintenance rationale.
Market insights and analysis
Platinum sensitivity is defined by a platinum-free interval over six months; patients have more treatment options and longer survival than in platinum-resistant disease, though most eventually become resistant.
Bevacizumab is a maintenance option, but contraindications, prior use, side effects, or patient preference can lead to observation instead.
ADC maintenance trials are ongoing; efficacy results remain early, and added adverse effects and use of topoisomerase-1 payloads are concerns.
Second-line PARP inhibitor maintenance use was withdrawn by the FDA after toxicity and overall-survival concerns.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Compugen
- AI-driven immuno-oncology pipeline advances with key AstraZeneca and Gilead partnerships.CGEN
Corporate presentation - Revenue doubled and clinical pipeline advanced, supporting a strong outlook into 2029.CGENQ2 2026
- Computationally driven immuno-oncology pipeline advances with key partnerships and adaptive trials.CGEN24th Annual Needham Virtual Healthcare Conference
- Rigorous computational discovery and validation drive novel immuno-oncology assets toward clinical success.CGENFireside chat
- AI-powered immuno-oncology pipeline advances with strong pharma partnerships and financial runway.CGENStifel 2026 Targeted Oncology Virtual Forum
- Up to $400M in securities offered to fund AI-driven cancer immunotherapy pipeline amid regional risks.CGENRegistration filing
- AI-powered immuno-oncology pipeline delivers novel antibodies and strong clinical progress.CGENInvestor presentation
- Strong cash reserves and advancing clinical pipeline support operations and milestones into 2029.CGENQ1 2026
- Computationally discovered immuno-oncology assets advance in pivotal trials and strategic partnerships.CGENLeerink’s Global Healthcare Conference 2025
Next Compugen earnings date
Q3 20269 Nov, 2026
Compugen
Next Compugen earnings date
Q3 20269 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Compugen Ltd. is a clinical-stage therapeutic discovery and development company that focuses on immuno-oncology and autoimmune diseases. The company leverages a predictive computational discovery platform to identify novel drug targets and develop therapeutic products. Its pipeline includes a range of products in clinical trials, such as COM701 and COM902, which target various cancers including non-small cell lung cancer and head and neck squamous cell carcinoma. The company is headquartered in Holon, Israel, and its shares are listed on the NASDAQ.